Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2016 - 2026)
Aurinia Pharmaceuticals (AUPH) posted Current Deferred Revenue of $5.0 million for Q1 2026, up 35.38% on a QoQ basis from $3.7 million in Q4 2025, and up 9.62% year-over-year from $4.6 million in Q1 2025.
Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $5.0 million for Q1 2026.
- Quarterly Current Deferred Revenue rose 9.62% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 9.62% YoY) and the FY2025 annual result came in at $3.7 million, down 66.19% from the prior year.
- Current Deferred Revenue was $5.0 million for Q1 2026 at Aurinia Pharmaceuticals, up from $3.7 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $11.0 million in Q4 2024 and bottomed at $3.1 million in Q4 2022.
- A 5-year average of $4.8 million and a median of $4.6 million in 2025 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 1556.84% — and 2025, when it plunged 66.19%.
- Aurinia Pharmaceuticals' Current Deferred Revenue stood at $3.1 million in 2022, then surged by 52.89% to $4.8 million in 2023, then soared by 128.59% to $11.0 million in 2024, then plunged by 66.19% to $3.7 million in 2025, then surged by 35.38% to $5.0 million in 2026.
- Business Quant data shows AUPH's Current Deferred Revenue at $5.0 million in Q1 2026, $3.7 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Aurinia Pharmaceuticals | 2.02 Bn | 1.64 Bn | 71.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.04 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 5.50 Mn |
| Mar 31, 2025 | 4.59 Mn |
| Dec 31, 2024 | 11.00 Mn |
| Sep 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Dec 31, 2023 | 4.81 Mn |
| Sep 30, 2023 | 4.66 Mn |
| Jun 30, 2023 | 3.23 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 3.15 Mn |
| Dec 31, 2021 | 190,000.00 |
| Dec 31, 2019 | 118,000.00 |
| Dec 31, 2018 | 118,000.00 |
| Dec 31, 2017 | 118,000.00 |
| Dec 31, 2016 | 118,000.00 |